HALO: Halozyme Therapeutics, Inc. - Summary | Jitta

Halozyme Therapeutics, Inc.

NASDAQ:HALO

Price
$40.11
Loss Chance
44.4%
4.73JITTA SCORE
32.32%Under Jitta Line
Jitta Ranking
37 / 1,142
420 / 5,003
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (65)
Recent Business Performance (61)
Financial Strength (52)
Return to Shareholders (50)
Competitive Advantage (68)
Jitta Signs
Share RepurchaseEvery Year
Revenue and EarningEarning loss detected in 2019
Operating MarginDeclined
Recent Business PerformanceEarning decline 13.58% in the last year
Key Stats
Jitta Score
Jitta Line
4.73
32.32%
1.28
412.73%
2.03
336.26%
Biotechnology
5.65
233.21%
5.15
551.17%
3.82
4.67%
COMPANY DESCRIPTION
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.